Glutamate dehydrogenase (GLDH) antibody is a polyclonal or monoclonal immunoglobulin designed to detect and quantify the mitochondrial enzyme glutamate dehydrogenase. GLDH catalyzes the reversible conversion of glutamate to α-ketoglutarate, a critical step in amino acid metabolism, the citric acid cycle, and urea synthesis . The antibody targets GLDH’s active site or epitopes, enabling its use in diagnostic assays, such as enzyme-linked immunosorbent assay (ELISA) or immunoprecipitation, to identify infections (e.g., Clostridioides difficile, Plasmodium falciparum) or assess liver injury .
GLDH antibodies are used to detect pathogens:
Clostridioides difficile: GLDH is a constitutively expressed enzyme in C. difficile. Enzyme immunoassay (EIA) for GLDH serves as a screening tool, followed by toxin detection .
Plasmodium falciparum: Recombinant P. falciparum GLDH (PfGDH) is targeted by polyclonal antibodies in ELISA, demonstrating 96.3% sensitivity and 100% specificity in detecting malaria .
A 2020 study demonstrated that anti-PfGDH antibodies effectively detect P. falciparum in human blood samples. Key results include:
Sample Types: Whole blood specimens showed higher affinity for PfGDH compared to serum or dried blood spots (DBS) .
Limitations: Antibodies against PfGDH peptides failed to bind, highlighting the need for full-length protein antigens .
A 2025 study validated GLDH’s utility in diagnosing hepatocellular injury:
Reference Intervals: Established in healthy populations to standardize GLDH measurements .
Tissue Specificity: GLDH levels remain unaffected by injury to tissues expressing GLDH (e.g., kidney, brain), confirming liver specificity .
Cross-Reactivity: Polyclonal antibodies may show non-specific binding, necessitating monoclonal antibodies (MAb) for enhanced precision .
Stability: GLDH in serum remains stable for 4 freeze-thaw cycles, enabling reliable longitudinal studies .